Login to Your Account

Codexis Prices, Too

After Mixed Phase III, Alimera Prices $72M IPO Below Range

By Trista Morrison

Friday, April 23, 2010
Four months after delivering mixed Phase III data on diabetic macular edema drug Iluvien, Alimera Sciences Inc. raised $72.1 million in its initial public offering. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription